What incretins are and why receptor count matters
Incretins are hormones the gut releases after eating that help regulate blood sugar and appetite. The two central ones are GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 stimulates insulin release in a glucose-dependent way, slows gastric emptying, and increases satiety through effects in the brain. GIP is a second incretin with its own metabolic effects.
The reason 'single, dual, and triple agonist' is a useful frame is that each of these drugs activates a different set of receptors. Semaglutide targets the GLP-1 receptor alone. Tirzepatide is a dual agonist that hits both the GIP and GLP-1 receptors. Retatrutide adds a third target, the glucagon receptor, on top of GIP and GLP-1. Glucagon-receptor agonism is thought to raise energy expenditure and mobilize fat from the liver.
How the mechanisms differ
Adding receptors is a strategy to broaden metabolic effect. GLP-1 activity drives much of the appetite suppression and slowed gastric emptying that these drugs are known for. Layering GIP activity on top, as tirzepatide does, is associated in trials with additional metabolic benefit and, in some analyses, better tolerability at comparable effect.
Retatrutide's glucagon-receptor component is the most distinct addition. Glucagon on its own would tend to raise blood sugar, but in the context of simultaneous GLP-1 and GIP activity, the intent is to capture glucagon's energy-expenditure and hepatic fat-mobilizing effects while the incretin activity keeps glucose in check.
Side-by-side comparison
The following is a simplified comparison. Reported weight-loss figures are trial averages that vary by dose, duration, and population, and they are not guarantees or head-to-head equivalents.
- Semaglutide — GLP-1 receptor agonist (single). Approved for type 2 diabetes and, at higher dose, obesity. Phase 3 obesity trials reported roughly 15% average body-weight reduction at 2.4 mg over about 68 weeks.
- Tirzepatide — GIP + GLP-1 receptor agonist (dual). Approved for type 2 diabetes and obesity. Phase 3 obesity trials reported roughly 21% at the highest dose over about 72 weeks.
- Retatrutide — GIP + GLP-1 + glucagon receptor agonist (triple). Investigational, not approved. A phase 2 obesity trial reported about 24% average reduction at the highest dose over 48 weeks, still needing phase 3 confirmation.
- Common thread — all three are titrated upward gradually and share dose-dependent gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation.
Approval status and why titration matters
Approval status is a hard line between these compounds. Semaglutide is FDA-approved and marketed under brand names including Ozempic and Rybelsus for type 2 diabetes and Wegovy for chronic weight management. Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and Zepbound for obesity. Retatrutide, by contrast, is investigational and has not been approved for any use.
Every one of these is escalated through a titration schedule, meaning the dose is stepped up gradually over weeks rather than started at the target level. The reason is tolerability: the gastrointestinal effects that come with incretin activity are strongly dose-dependent, and slow escalation gives the body time to adapt. Titration is central to how these agents are used safely under medical supervision.
Research material versus prescription reality
There is a critical difference between an approved prescription product and material sold as 'for research use only.' Prescription incretins are pharmaceutical-grade, manufactured to strict standards, prescribed for defined indications, and used with medical monitoring. Research-use material carries none of those guarantees: identity, purity, sterility, and dose accuracy are not assured, and such material is not intended or approved for human use.
This page is educational only and is not medical advice. Describing how approved drugs are dosed and titrated is factual background about the medicines, not a protocol for anyone to follow. Decisions about diabetes, weight, or any metabolic condition belong with a qualified clinician.